Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial

被引：0
|
作者：
Guttman-Yassky, Emma [1 ]
Beck, Lisa A. [2 ]
Anderson, Jaclyn K. [3 ]
Hu, Xiaofei [3 ]
Gu, Yihua [3 ]
Teixeira, Henrique D. [3 ]
Silverberg, Jonathan I. [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, Med Ctr, New York, NY 10029 USA
[2] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
8318
引用
收藏
页码：AB294 / AB294
页数：1
相关论文
共 50 条
  • [41] Discontinuation of topical corticosteroids in upadacitinib-treated patients with moderate-to-severe atopic dermatitis: analysis from the AD Up phase III trial
    Reich, K.
    Boguniewicz, M.
    Kabashima, K.
    Barbarot, S.
    Girolomoni, G.
    Mendes-Bastos, P.
    Gamelli, A.
    Liu, Y.
    Teixeira, H.
    Armstrong, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E118 - E118
  • [42] Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
    Blauvelt, Andrew
    Ladizinski, Barry
    Prajapati, Vimal H.
    Laquer, Vivian
    Fischer, Alison
    Eisman, Samantha
    Hu, Xiaofei
    Wu, Tianshuang
    Calimlim, Brian M.
    Kaplan, Blair
    Liu, Yingyi
    Teixeira, Henrique D.
    Liu, John
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 478 - 485
  • [43] Upadacitinib normalizes the lesional and nonlesional cutaneous transcriptome in patients with moderate-to-severe atopic dermatitis
    Smith, K. M.
    Chen, X.
    Tsoi, L. C.
    Bi, Y.
    Gudjonsson, J.
    Parmentier, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S138 - S138
  • [44] Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
    Guttman-Yassky, Emma
    Esfandiari, Ehsanollah
    Mano, Hirotaka
    Arai, Takahiro
    Kabashima, Kenji
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [45] Baricitinib for the treatment of pediatric patients with moderate-to-severe atopic dermatitis
    Paller, Amy
    Chu, Chia-Yu
    Yang, Chin-Yi
    Janes, Jonathan
    Prakash, Apurva
    Rueda, Maria Jose
    Stanley, Sarah
    Wu, Wen-Shuo
    Zhang, Xin
    Eichenfield, Lawrence
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB108 - AB108
  • [46] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [47] Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results
    Silverberg, Jonathan, I
    Guttman-Yassky, Emma
    Simpson, Eric L.
    Papp, Kim A.
    Blauvelt, Andrew
    Chu, Chia-Yu
    Hong, H. Chih-ho
    Gold, Linda F. Stein
    Bieber, Thomas
    Kabashima, Kenji
    Rosmarin, David
    Gamelli, Amy
    Calimlim, Brian
    Vigna, Namita
    Hu, Xiaofei
    Yang, Yang
    Wu, Xiaoqiang
    Huang, Xiaohong
    Suravaram, Smitha
    Teixeira, Henrique D.
    Raymundo, Eliza
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II8 - II8
  • [48] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    Dermatology and Therapy, 2023, 13 : 595 - 608
  • [49] Upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the Heads Up phase III trial
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    Costanzo, A.
    De Bruin-Weller, M.
    Barbarot, S.
    Prajapati, V. H.
    Lio, P.
    Hu, X.
    Wu, T.
    Liu, J.
    Ladizinski, B.
    Chu, A. D.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E123 - E123
  • [50] Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    Guttman-Yassky, Emma
    Thaci, Diamant
    Pangan, Aileen L.
    Hong, H. Chih-ho
    Papp, Kim A.
    Reich, Kristian
    Beck, Lisa A.
    Mohamed, Mohamed-Eslam F.
    Othman, Ahmed A.
    Anderson, Jaclyn K.
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (03) : 877 - 884
12345